The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the growing importance of analyzing genetic abnormalities in patients with chronic lymphocytic leukemia (CLL). Beyond the traditional use of next-generation sequencing (NGS) at the time of progression, emerging data suggest that abnormalities in genes involved in BCR signaling, epigenetic regulation, and transcriptional factors may impact time-to-first treatment, helping to identify patients who require closer follow-up or may be candidates for early intervention. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
